Core Insights - Telomir Pharmaceuticals, Inc. has announced new cellular study results indicating that Telomir-1, in the form of Telomir-Zn, modulates intracellular metal balance linked to oxidative stress and mitochondrial dysfunction [1] Group 1: Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing small-molecule therapeutics targeting biological mechanisms involved in cancer, aging, and degenerative diseases [1] Group 2: Study Findings - The study demonstrates that Telomir-Zn induces a rapid and coordinated intracellular redistribution of zinc and iron [1] - The modulation of metal balance occurs without relying on cytotoxic mechanisms, suggesting a novel approach to addressing oxidative stress and genomic integrity [1]